SEC Form 3 · accession 0001144204-18-066584
Marker Therapeutics, Inc. · MRKR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ann M. Leen
Officer — Chief Scientific Officer
Period of report
Dec 21, 2018
Accepted (ET)
Dec 28, 2018 · 4:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001094038
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 1,993,059 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants to Acquire Common Stock | $2.99 | holding | — | — | — | Oct 17, 2018 | Oct 17, 2023 | Common Stock | 722,783 | — | D |
| Employee Stock Option (Right to Buy)F1 | $9.18 | holding | — | — | — | — | Oct 19, 2028 | Common Stock | 500,000 | — | D |
Explanation of responses
- F1Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, that were granted in connection with entering into a consulting agreement with the Company to serve as the Company's Chief Scientific Officer. One quarter of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal monthly installments over a three year period upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 19, 2018.
Remarks
* Mr. Mark A. Catchur is signing as Attorney-in-Fact pursuant to power of attorney dated December 21, 2018 granted by each Reporting Person, a copy of which is filed as an exhibit and incorporated herein by reference.